Ultragenyx Pharmaceutical Inc. (RARE)

39,05 -4,07 (-9,44%) Börsenschluss: 04:00PM EDT

Ultragenyx Pharmaceutical Inc.

60 Leveroni Court
Novato, CA 94949
United States
415 483 8800
https://www.ultragenyx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 1.276

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Emil D. Kakkis M.D., Ph.D.	Founder, President, CEO & Director	1,46M	1,27M	1960
Mr. Howard Horn	Executive VP of Corporate Strategy & CFO	184,81k	N/A	1978
Ms. Karah Herdman Parschauer J.D.	Chief Legal Officer & Executive VP of Corporate Affairs	846,74k	N/A	1978
Mr. John Richard Pinion II	Chief Quality Operations Officer & Executive VP of Translational Sciences	860,05k	N/A	1966
Mr. Erik Harris	Executive VP & Chief Commercial Officer	878,77k	N/A	1971
Mr. Theodore A. Huizenga	Senior VP, Corporate Controller & Principal Accounting Officer	N/A	N/A	1971
Mr. Ernie W. Meyer	Chief Human Resources Officer & Executive VP	N/A	N/A	1965
Mr. Thomas R. Kassberg	Chief Business Officer & Executive VP	714,84k	N/A	1960
Mr. Vimal Srivastava	Senior Vice President of Business Development & Alliance Management	N/A	N/A	1965
Mr. Dennis Karl Huang	Chief Technical Operations Officer and EVP of Gene Therapy Research & Development	331,33k	N/A	1965

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Corporate Governance

Ultragenyx Pharmaceutical Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 6. Die grundlegenden Scores sind Audit: 2, Vorstand: 1, Shareholderrechte: 7, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.